Introduction
Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract with heterogeneous characteristics, in which disease location is associated with differences in biology and therapeutic response (1). However, blood-based biomarkers reflecting location-specific CD phenotypes are lacking (2). Tryptophan metabolism, including serotonin, plays an important role in intestinal inflammation (3), but its association with disease location remains unclear (4). Our aim was to evaluate whether plasma tryptophan metabolites differ by disease location and to assess the clinical relevance of serotonin as a biomarker to distinguish ileal from colonic CD.
Aims & Methods
Plasma levels of 20 tryptophan metabolites were quantified using liquid chromatography coupled to quadrupole mass spectrometry (LC-MS/MS) in CD patients and healthy (non-CD) controls (HC, n=10). Disease location was classified according to the Montreal classification as ileal (L1), colonic (L2), or ileocolonic (L3). Patients with upper gastrointestinal involvement (L4) were included within their primary location group. Quiescent disease was defined as Harvey–Bradshaw Index (HBI) <5 combined with serum C-reactive protein (CRP) <5 mg/L. The overall CD cohort was included in the analyses and stratified by disease activity. Tryptophan metabolite levels were compared using the Kruskal–Wallis test. Receiver operating characteristic (ROC) analysis was performed to assess discrimination of ileal versus colonic CD.
Results
In total, 38 CD patients (L1 n=12, L2 n=8, L3 n=18), including 18 with active disease (L1 n=3, L2 n=3, L3 n=12) and 20 quiescent patients (L1 n=9, L2 n=5, L3 n=6), as well as 10 HC, were included. Among the 20 metabolites analyzed, serotonin was the only metabolite showing a consistent association with disease location. Plasma serotonin levels were significantly lower in L2 compared to L1 and L3 in the overall cohort (p=0.007), with similar findings in the active disease group (p=0.037). The same directional trend was observed in quiescent CD patients, but this did not reach statistical significance (p=0.098). Compared to HC, L2 patients showed reduced serotonin levels, whereas serotonin levels in L1 patients were comparable to HC. Patients with L3 CD showed a trend toward higher serotonin levels compared to HC, although this was not statistically significant. ROC analysis demonstrated good discrimination between L2 and non-colonic CD (both L1 and L3), with an area under the curve (AUC) of 0.86 (total cohort), 0.97 (active CD), and 0.80 (quiescent CD). CRP levels did not differ significantly across location groups.
Conclusion
Blood-based serotonin differs by disease location in CD, with reduced levels in colonic disease and relative preservation in ileal and ileocolonic disease. CRP levels were comparable across locations, supporting that serotonin reflects location-specific biology rather than differences in systemic inflammatory burden. These findings may explain inconsistencies in previous studies of circulating serotonin in CD and suggest that disease location should be considered when interpreting serotonergic pathways and their potential therapeutic modulation.
References
- Kolho KL, Paavola A, Sipponen T, et al. Serum analysis of tryptophan catabolism pathway: correlation with Crohn's disease activity. Inflamm Bowel Dis. 2011;17(11):2175-2182. doi:10.1002/ibd.21624
- Zhang Y, Li Y, Wang X, et al. The involvement of intestinal tryptophan metabolism in inflammatory bowel disease (IBD): an update. Front Immunol. 2023;14:1217570. doi:10.3389/fimmu.2023.1217570
- Wiśniewska-Jarosińska M, Drzewoski J, Nieciecki M, et al. Evaluation of tryptophan and its metabolites in predicting disease activity in inflammatory bowel disease. Prz Gastroenterol. 2025;20(1):12-20. doi:10.5114/pg.2025.134567
- Banskota S, Khan WI. Serotonin in the gut: Blessing or a curse during inflammatory bowel diseases. Front Immunol. 2021;12:700621. doi:10.3389/fimmu.2021.700621
Disclosure
Mark Löwenberg: consultancy/lecture fees from Abbvie, Bristol Myers Squibb, Eli Lilly, Galapagos, Janssen-Cilag, Johnson & Johnson, Medtronic, Pfizer, Takeda, Tillotts. Grants received from ZonMW, Alfasigma, NFU transformation deal and TKI. Geert R.A.M. D'Haens: served as a consultant for AbbVie, Alimentiv, AstraZeneca, Bristol Myers Squibb, Celltrion, Eli Lilly, Exeliom Biosciences, Johnson & Johnson, Pfizer, and Takeda; and has received speakers bureau fees from AbbVie, Eli Lilly, Pfizer, Bristol Myers Squibb, and Takeda. Wouter J. de Jonge:received grant support from Leona M and Harry B Helmsley Charitable Trust, TKI Health Holland, BMS, Reckitt, Friesland Campina and the European Commission; speaker fees from Janssen Cilag, Alimentiv, and IBD Canada; is scientific board member of the MDL fund. Mohammed Ghiboub: received grants from Amsterdam Gastroenterology Endocrinology Metabolism, Crohn's & Colitis Foundation, and the European Crohn's and Colitis Organisation.